Repeat pull from proven relationships plus room left

Surmodics, Inc. (SRDX) — this company's answers

The model's full reasoning — Q3 2018 call → NOWe need to determine if management describes existing customers/partners taking more on their own initiative, and that these relationships remain lightly penetrated. Let's examine the transcript. Key points: - Revenue growth driven by broad strength in hydrophilic coatings royalties, and $1.7M license fee from Abbott SurVeil agreement. - Abbott deal: They have options for below-the-knee and AV fistula programs. The SurVeil agreement is a partnership. Is Abbott an existing customer? They are a new partner for SurVeil, but they are a large customer? The transcript mentions "our largest customer" in a question about Medtronic. Actually, the question from Brooks O'Neil: "I'm curious if I was listening correctly, it sounds like your entertaining conversations with multiple potential partners and products -- whole products you're developing. I'm just curious how all of this plays with the various children you're engaged with including obviously Medtronic your largest customer, Abbott your newest large partner..." So Abbott is a new partner, not an existing customer that is expanding. The revenue from Abbott is a license fee, not a reorder or expansion. It's a one-time upfront fee recognized over time. That's not expansion behavior. - The medical device product sales increased 49% due to "substantial increase in balloon catheter unit volume as a result of recent customer product launches" - that suggests existing customers launching products that use Surmodics' components. That could be expansion. But is it described as customers taking more on their own initiative? It says "recent customer product launches" - that implies customers are launching new products that incorporate Surmodics' technology, so they are taking more volume. But is that a deepening of existing relationships? Possibly. However, the question asks about "counterparties the company has ALREADY SERVED AND PROVEN ITSELF WITH" - existing customers. The transcript mentions "broad strength in our hydrophilic coatings royalties" - that could be existing customers using more coatings. But is there any explicit statement that these relationships are lightly penetrated? - The IVD business: "strong growth in antigen and stabilizer sales" - that's existing products. But no mention of expansion or room. - The whole product solutions: They have .014 and .018 balloons, microcatheter, etc.

← Back to the full SRDX analysis